clinical trial · NCT04991116
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Psoriatic ArthritisTILD sub-cutaneous (SC) injection
brief summary
An open label phase 3 study
started
Jun 30, 2022
primary completion
Dec 1, 2028
completion
Apr 1, 2029
last updated
Mar 5, 2026
detailed description
Subjects from both INSPIRE 1 (TILD-19-07) and INSPIRE 2 (TILD-19-19) studies to roll over into this INSPIRE LTE study (TILD-21-01).
official title
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol